Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares the analgesic effect of intranasal sub-dissociative dosing of ketamine and intranasal fentanyl in children presenting to the Emergency Department with acute extremity injuries.
Inadequate pain control, especially in the emergency department (ED), is a major public health concern. Despite increased awareness, pain continues to be underdiagnosed and undertreated, particularly in the pediatric population. Children often encounter long delays in medication administration, possibly due to the time required to obtain intravenous access. The intranasal administration route offers a more efficient alternative for faster and noninvasive delivery of pain medication. This route is gaining popularity secondary to its rapid onset of active, minimal discomfort and relative simplicity.
Opioids are the most commonly used class of analgesic pain medication for children presenting in severe pain due to traumatic injuries. Despite their potential effectiveness, opioids have several concerning adverse effects, particularly when administered prior to procedural sedation in children. Administration of pre-procedural sedation opioids is associated with an increased risk of serious adverse events (oxygen desaturation, apnea, and hypotension) as well as the need for significant interventions, such as bag-mask ventilation, intubation, and pharmacologic blood pressure support. In addition, due to genetic variations that may lead to increased or diminished opioid sensitivity, ideal dosing to adequately control severe pain yet avoid adverse medication-related side effects is difficult to ascertain. Many children in severe pain do not receive opioids, receive doses that are below those recommended or experience long delays in receiving opioids. The reasons for this are unclear, but the investigators speculate that this may be due in part to fear of adverse effects of opioids, provider inexperience with opioid use in children or fear of contributing to opioid tolerance or abuse. For all of these reasons, providers often seek non-opioid alternatives for pediatric patients with acute, severe pain.
Ketamine, in sub-dissociative doses administered by the intravenous or intranasal route, is emerging as an alternative medication for the treatment of moderate to severe pain in multiple settings. In adults, low dose ketamine is well tolerated and has been used successfully as an adjuvant and an alternative to opioids to provide rapid pain relief in the ED. As a dissociative anesthetic, ketamine is the most commonly used agent to facilitate painful procedures in the pediatric emergency department. At lower doses, it has been used in children to provide analgesia in a variety of acute and chronic pain settings, including terminal diagnoses, sickle cell disease, perioperative pain, traumatic injuries, extensive burns and conditions where opioids are contraindicated. Similar to adults, ketamine has been used via the intranasal route to provide adequate analgesia and sedation in children in the pre-hospital setting and in those undergoing procedures.
The objective of this study is to compare intranasal sub-dissociative ketamine with intranasal fentanyl for treatment of acute pain associated with traumatic limb injuries in children presenting to the ED and to document an objective respiratory side effect profile utilizing noninvasive capnometry. If found to be an effective analgesic, intranasal ketamine would be particularly useful in children who experience adverse effects with opioids, have developed opioid tolerance as a result of chronic painful conditions, have poor opioid sensitivity due to their genetic predisposition or in pediatric trauma patients with the potential for hypotension. Additionally, for patients that require procedural sedation for fracture reduction, avoiding opioids early in the emergency department visit may decrease sedation recovery time and the risk of serious adverse events during sedation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketamine | Experimental | Ketamine 1.5 mg/kg intranasally for one dose |
|
| Fentanyl | Active Comparator | Fentanyl 2 mcg/kg intranasally for one dose |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine | Drug |
|
| |
| Fentanyl |
| Measure | Description | Time Frame |
|---|---|---|
| Difference From Baseline in Visual Analog Scale Pain Score | A VAS score is a self reported pain score of 0-100 millimeters (0 = no pain; 100 = worst possible pain). A decrease in a VAS score indicates a decrease in pain severity. | 30 minutes after study medication |
| Measure | Description | Time Frame |
|---|---|---|
| Difference From Baseline in Visual Analog Scale Pain Score | A VAS score is a self reported pain score of 0-100 millimeters (0 = no pain; 100 = worst possible pain). A decrease in a VAS score indicates a decrease in pain severity. | 15 minutes after study medication |
| Difference From Baseline in Visual Analog Scale Pain Score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Theresa M Frey, MD | Children's Hospital Medical Center, Cincinnati | Principal Investigator |
| Matthew R Mittiga, MD | Children's Hospital Medical Center, Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30592476 | Derived | Frey TM, Florin TA, Caruso M, Zhang N, Zhang Y, Mittiga MR. Effect of Intranasal Ketamine vs Fentanyl on Pain Reduction for Extremity Injuries in Children: The PRIME Randomized Clinical Trial. JAMA Pediatr. 2019 Feb 1;173(2):140-146. doi: 10.1001/jamapediatrics.2018.4582. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial took place at a tertiary care children's hospital emergency department from March 2016 to February 2017. The study sample was identified through an established triage process identifying children with an acute painful extremity injury. These patients were ages 8-17 years with a visual analog scale (VAS) score greater than 35 mm.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ketamine | Ketamine 1.5 mg/kg intranasally for one dose |
| FG001 | Fentanyl | Fentanyl 2 mcg/kg intranasally for one dose |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ketamine | Ketamine 1.5 mg/kg intranasally for one dose |
| BG001 | Fentanyl | Fentanyl 2 mcg/kg intranasally for one dose |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Difference From Baseline in Visual Analog Scale Pain Score | A VAS score is a self reported pain score of 0-100 millimeters (0 = no pain; 100 = worst possible pain). A decrease in a VAS score indicates a decrease in pain severity. | One patient in the ketamine group did not have a baseline pain score documented and four patients withdrew from the study (1 in the ketamine group, 3 in the fentanyl group), resulting in 43 patients randomized to the ketamine group and 42 patients randomized to the fentanyl group included in the primary outcome analysis. | Posted | Mean | 95% Confidence Interval | score on a scale | 30 minutes after study medication |
|
30 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ketamine | Ketamine 1.5 mg/kg intranasally for one dose | 0 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dizziness | Nervous system disorders | Non-systematic Assessment |
Convenience sample; 4 patients withdrew before medication given; Conservative choice of non-inferiority margin; Interventions like splinting or child life presence were not assessed; Rescue analgesia was at the discretion of the primary provider
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Theresa Frey, MD | Cincinnati Children's Hospital Medical Center | 513-636-7966 | theresa.frey@cchmc.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 26, 2018 | Mar 3, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D005283 | Fentanyl |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
A VAS score is a self reported pain score of 0-100 millimeters (0 = no pain; 100 = worst possible pain). A decrease in a VAS score indicates a decrease in pain severity. |
| 60 minutes after study medication |
| Highest Achieved University of Michigan Sedation Scale (UMSS) Score | The University of Michigan Sedation Scale is a valid and reliable tool that allows for rapid assessment of the depth of sedation in children. It is a simple observational tool that assesses the level of alertness on a five-point scale. It has been validated in children and has shown to have significant inter-rater reliability. Score is 0-4 (0 = awake and alert; 1= minimally sedated; 2 = moderately sedated; 3 = deeply sedated; 4 = unarousable) | 15, 30, and 60 minutes after study medication administration |
| Rescue Analgesia | Documentation of additional pain medication after study medication administration | Within the first 60 minutes after study medication |
| Heart Rate | 15 minutes after study medication |
| Heart Rate | 30 minutes after study medication |
| Heart Rate | 60 minutes after study medication |
| Respiratory Rate | 15 minutes after study medication |
| Respiratory Rate | 30 minutes after study medication |
| Respiratory Rate | 60 minutes after study medication |
| Systolic Blood Pressure | 15 minutes after study medication |
| Systolic Blood Pressure | 30 minutes after study medication |
| Systolic Blood Pressure | 60 minutes after study medication |
| Diastolic Blood Pressure | 15 minutes after study medication |
| Diastolic Blood Pressure | 30 minutes after study medication |
| Diastolic Blood Pressure | 60 minutes after study medication |
| Oxygen Saturation | 15 minutes after study medication |
| Oxygen Saturation | 30 minutes after study medication |
| Oxygen Saturation | 60 minutes after study medication |
| Capnometry Value | 15 minutes after study medication |
| Capnometry Value | 30 minutes after study medication |
| Capnometry Value | 60 minutes after study medication |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Weight | Mean | Standard Deviation | kilograms |
|
| Mechanism of Injury | Count of Participants | Participants |
|
| Time of injury prior to arrival | Median | Inter-Quartile Range | minutes |
|
| Extremity | Three participants had more than one extremity involved. Therefore, percentages do not add up to 100. | Number | participants |
|
| Diagnosis | Two participants had both a fracture and a dislocation. | Number | participants |
|
| Reduction Required | Count of Participants | Participants |
|
| Sedation Required | Count of Participants | Participants |
|
| Analgesic Prior to Arrival | Count of Participants | Participants |
|
| Initial VAS score | The Visual Analog Scale is a pain scale ranging from 0 mm (no pain) to 100 mm (worst possible pain) that has been shown to be valid and reliable in children 8 to 17 years of age suffering from acute pain. A minimum clinically significant difference in VAS score ranges from 10 to 12 mm. in children and adolescents. The optimal cut off points between mild, moderate, and severe pain are 35 mm and 60 mm. | One patient in the Ketamine group did not have a baseline pain score documented. | Mean | Standard Deviation | score on a scale |
|
| Baseline Heart Rate | Mean | Standard Deviation | beats per minute |
|
| Baseline Respiratory Rate | Mean | Standard Deviation | breaths per minute |
|
| Baseline Systolic Blood Pressure | Mean | Standard Deviation | mmHg |
|
| Baseline Diastolic Blood Pressure | Mean | Standard Deviation | mmHg |
|
| Baseline Oxygen Saturation | Mean | Standard Deviation | percent |
|
| Baseline End Tidal Captometry | Mean | Standard Deviation | mmHg |
|
| Time to Study Medication from Arrival | Mean | Standard Deviation | minutes |
|
| Volume of Study Medication Administered | Median | Inter-Quartile Range | milliliters |
|
| Dose of Study Medication Administered (Ketamine) | Participants receiving Fentanyl did not receive Ketamine | Median | Inter-Quartile Range | milligrams per kilogram (mg/kg) |
|
| Dose of Study Medication Administered (Fentanyl) | Participants receiving Ketamine did not receive Fentanyl | Median | Inter-Quartile Range | micrograms per kilogram (mcg/kg) |
|
Fentanyl 2 mcg/kg intranasally for one dose |
|
|
| Secondary | Difference From Baseline in Visual Analog Scale Pain Score | A VAS score is a self reported pain score of 0-100 millimeters (0 = no pain; 100 = worst possible pain). A decrease in a VAS score indicates a decrease in pain severity. | One patient in the ketamine group did not have a baseline pain score documented and four patients withdrew from the study (1 in the ketamine group, 3 in the fentanyl group), resulting in 43 patients randomized to the ketamine group and 42 patients randomized to the fentanyl group included in this secondary outcome analysis. | Posted | Mean | 95% Confidence Interval | score on a scale | 15 minutes after study medication |
|
|
|
| Secondary | Difference From Baseline in Visual Analog Scale Pain Score | A VAS score is a self reported pain score of 0-100 millimeters (0 = no pain; 100 = worst possible pain). A decrease in a VAS score indicates a decrease in pain severity. | One patient in the ketamine group did not have a baseline pain score documented and four patients withdrew from the study (1 in the ketamine group, 3 in the fentanyl group), resulting in 43 patients randomized to the ketamine group and 42 patients randomized to the fentanyl group included in this secondary outcome analysis. | Posted | Mean | 95% Confidence Interval | score on a scale | 60 minutes after study medication |
|
|
|
| Secondary | Highest Achieved University of Michigan Sedation Scale (UMSS) Score | The University of Michigan Sedation Scale is a valid and reliable tool that allows for rapid assessment of the depth of sedation in children. It is a simple observational tool that assesses the level of alertness on a five-point scale. It has been validated in children and has shown to have significant inter-rater reliability. Score is 0-4 (0 = awake and alert; 1= minimally sedated; 2 = moderately sedated; 3 = deeply sedated; 4 = unarousable) | Posted | Count of Participants | Participants | 15, 30, and 60 minutes after study medication administration |
|
|
|
| Secondary | Rescue Analgesia | Documentation of additional pain medication after study medication administration | Posted | Count of Participants | Participants | Within the first 60 minutes after study medication |
|
|
|
| Secondary | Heart Rate | Posted | Mean | Standard Deviation | beats per minute | 15 minutes after study medication |
|
|
|
| Secondary | Heart Rate | Posted | Mean | Standard Deviation | beats per minute | 30 minutes after study medication |
|
|
|
| Secondary | Heart Rate | Posted | Mean | Standard Deviation | beats per minute | 60 minutes after study medication |
|
|
|
| Secondary | Respiratory Rate | Posted | Mean | Standard Deviation | breaths per minute | 15 minutes after study medication |
|
|
|
| Secondary | Respiratory Rate | Posted | Mean | Standard Deviation | breaths per minute | 30 minutes after study medication |
|
|
|
| Secondary | Respiratory Rate | Posted | Mean | Standard Deviation | breaths per minute | 60 minutes after study medication |
|
|
|
| Secondary | Systolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | 15 minutes after study medication |
|
|
|
| Secondary | Systolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | 30 minutes after study medication |
|
|
|
| Secondary | Systolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | 60 minutes after study medication |
|
|
|
| Secondary | Diastolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | 15 minutes after study medication |
|
|
|
| Secondary | Diastolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | 30 minutes after study medication |
|
|
|
| Secondary | Diastolic Blood Pressure | Posted | Mean | Standard Deviation | mmHg | 60 minutes after study medication |
|
|
|
| Secondary | Oxygen Saturation | Posted | Mean | Standard Deviation | percent | 15 minutes after study medication |
|
|
|
| Secondary | Oxygen Saturation | Posted | Mean | Standard Deviation | percent | 30 minutes after study medication |
|
|
|
| Secondary | Oxygen Saturation | Posted | Mean | Standard Deviation | percent | 60 minutes after study medication |
|
|
|
| Secondary | Capnometry Value | Posted | Mean | Standard Deviation | mmHg | 15 minutes after study medication |
|
|
|
| Secondary | Capnometry Value | Posted | Mean | Standard Deviation | mmHg | 30 minutes after study medication |
|
|
|
| Secondary | Capnometry Value | Posted | Mean | Standard Deviation | mmHg | 60 minutes after study medication |
|
|
|
| 44 |
| 0 |
| 44 |
| 34 |
| 44 |
| EG001 | Fentanyl | Fentanyl 2 mcg/kg intranasally for one dose | 0 | 42 | 0 | 42 | 13 | 42 |
| Dysphoria/Dissociation | Nervous system disorders | Non-systematic Assessment |
|
| Unpleasant Taste | Gastrointestinal disorders | Non-systematic Assessment |
|
| Drowsiness | Nervous system disorders | Non-systematic Assessment |
|
| Nausea/Vomiting | Gastrointestinal disorders | Non-systematic Assessment |
|
| Pruritis | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
|
| Vision Changes | Eye disorders | Non-systematic Assessment |
|
| Headache | Nervous system disorders | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Non-systematic Assessment |
|
| Lightheadedness | Nervous system disorders | Non-systematic Assessment |
|
| Nystagmus | Eye disorders | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| Hispanic |
|
| Other |
|
| Fall |
|
| Other |
|
| Naproxen |
|
| No Analgesic |
|
| UMSS 2 |
|
| Morphine |
|
| Ketamine |
|
| Toradol |
|
| No rescue analgesia |
|